World Kinect (NYSE:WKC) reports quarterly earnings below forecasts, with revenue decline and net margin pressures reflecting ...

This week, Engadget Managing Editor Cherlynn Low joins us to look back at some of the highlights (and lowlights) of 2025.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in pediatric and adult participants who ...

Biosciences announced that its Phase 3 KINECT-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in ...

Permit us to toot our own horn for a brief moment. GamesIndustry.biz put out an incredible range of features in 2025, and ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety ...

Nex Playground has objectively shaken up the console market. During Black Friday weekend in November, the motion-gaming console surged past Xbox in U.S. weekly hardware sales, an upset that instantly ...

San Diego, USA-based Neurocrine Biosciences announced that its Phase III KINECT-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in pediatric and adult participants who have ...

The KINECT-DCP trial evaluated the efficacy and safety of valbenazine in patients with dyskinesia due to cerebral palsy who experience choreiform movements.

Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. | Neurocrine’s Ingrezza, approved to treat certain uncontrolled movements, failed to ...